Tofacitinib en el tratamiento de la colitis ulcerosa: casos clínicos
Biological therapy dramatically changed the management of Ulcerative Colitis (UC). However, a significant number of these patients fail to respond or have secondary loss of response to this strategy. In this clinical situation, the options include intensification of anti-TNF therapy, the use of a second anti-TNF or being switched to another drug class. Among the later, tofacitinib, an oral small molecule directed against the JAK/STAT pathway, is safe and effective in inducing and maintaining remission in patients with moderate-severe UC. We report two patients with UC refractory to conventional treatment and biological therapy, who responded successfully to the use of tofacitinib.
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Digital revista |
| Language: | Spanish / Castilian |
| Published: |
Sociedad Médica de Santiago
2020
|
| Online Access: | http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872020000701039 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|